Benralizumab is a medicine for severe asthma and a few other conditions caused by too many eosinophils, a type of white blood cell. It is given as an injection under the skin every few weeks. It works by helping the body clear out those eosinophils, which calms swelling in the airways and other parts of the body.
Every report comes from a Lived member, sent anonymously.
Have you tried Fasenra (Benralizumab) for Asthma?
Benralizumab, sold as Fasenra, is a prescription injection for conditions driven by eosinophils, a type of white blood cell that causes inflammation and tissue damage when there are too many of them. Its main use is severe eosinophilic asthma in adults and children 6 and older. This is severe asthma in which eosinophil-driven inflammation plays a large part, usually shown by raised eosinophil counts in the blood and repeated attacks despite strong inhaled treatment. For asthma, benralizumab is an add-on: it is used alongside existing controller inhalers, not in place of them. It is also approved for two rarer conditions. Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of vasculitis, meaning inflammation of blood vessels, that typically develops in people with asthma and very high eosinophil counts; benralizumab is approved for adults with EGPA. Hypereosinophilic syndrome (HES) is a group of disorders in which persistently high eosinophil counts damage organs; benralizumab is approved for people 12 and older whose HES is not explained by an outside cause such as a drug reaction, a parasitic infection or a cancer outside the blood system. Benralizumab is one of several injectable biologic medicines for severe asthma. Mepolizumab (Nucala) is a close relative that acts on the same eosinophil signaling pathway at a different point.
Eosinophils rely on a signaling protein called interleukin-5 (IL-5) to become activated and survive. In eosinophilic asthma they contribute to the swelling and irritation of the airways that lead to attacks, and in EGPA and HES they contribute to inflammation in blood vessels and organs. Benralizumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds to the IL-5 receptor on the surface of eosinophils and flags those cells for destruction by the immune system's natural killer cells. As a result, eosinophil counts in the blood start falling within a day of the first dose and are typically close to zero by four weeks, staying low with continued treatment. Removing eosinophils lowers one important source of inflammation. That is why the drug's benefit shows up as fewer flare-ups and less need for steroids, rather than as instant opening of the airways. Researchers have not fully established how eosinophil depletion produces the benefit in each of the three conditions.
Benralizumab is injected under the skin of the thigh or abdomen, or the upper arm when someone else gives it. Each dose is one injection. For asthma, the usual schedule is 30 mg every 4 weeks for the first three doses, then every 8 weeks after that. Children 6 to 11 who weigh less than 35 kg (about 77 pounds) receive a 10 mg dose on the same schedule. For EGPA and HES, the dose is 30 mg every 4 weeks throughout. The prefilled syringe is given by a healthcare professional, and clinics generally observe people for a short time after a biologic injection in case of an allergic reaction. When the prescriber agrees, the Fasenra Pen, a single-use autoinjector, can be used at home by the patient or a caregiver after training. Children 6 to 11 do not inject themselves; a caregiver or clinician gives the pen. Before injecting, the pen sits at room temperature for about 30 minutes, and liquid that looks cloudy, discolored or has large particles should not be used. If a dose is missed, call the prescriber for advice on when to take it. Benralizumab does not relieve a sudden asthma attack. A rescue (quick-relief) inhaler is still needed for that, and other asthma medicines should continue unless the care team changes them.
Most people tolerate benralizumab well. In asthma trials, the most common side effects were headache and sore throat, with occasional fever and mild injection-site reactions such as pain, redness or itching. People treated for HES more often reported headache, allergic-type reactions and flu-like symptoms. Allergic reactions are the main serious risk. They usually begin within hours of an injection but occasionally appear days later. Hives or a new rash after a dose should be reported to the prescriber promptly. Call 911 for trouble breathing, swelling of the face, lips, mouth or tongue, or fainting, because these can signal anaphylaxis, a severe whole-body allergic reaction. Someone who has had an allergic reaction to benralizumab should not receive it again.
Starting benralizumab does not mean stopping steroids. Inhaled steroids and steroid tablets such as prednisone should not be stopped suddenly. If the drug works well, the prescriber may lower steroid tablets gradually and under supervision. Cutting down too quickly can cause steroid withdrawal symptoms and can bring out other conditions the steroids had been keeping under control. Eosinophils may help the body fight parasitic worm infections. An existing worm infection should be treated before starting benralizumab, and if one develops during treatment and does not clear with anti-parasite medicine, benralizumab is paused until it does. The prescriber and pharmacist should also know about all other medicines and supplements. There is too little information from pregnant people to know whether benralizumab affects a pregnancy. Antibodies like this one cross the placenta mainly in the third trimester. Poorly controlled asthma itself raises the risk of preeclampsia (a pregnancy complication involving high blood pressure) and of babies being born early or small, so anyone pregnant or planning pregnancy should weigh both sides with the care team rather than stopping on their own. Whether benralizumab passes into breast milk is not known.
Eosinophil counts drop quickly, but the benefit people notice is mainly fewer and milder flare-ups, which takes months to judge. Across clinical trials in severe eosinophilic asthma, drugs in this group roughly halved the number of attacks needing steroid tablets. Among adults who depended on daily steroid tablets, the typical dose reduction with benralizumab was 75%, compared with 25% on placebo, while asthma stayed controlled. Breathing tests and day-to-day symptom scores improved only modestly on average, so some people feel little different between attacks. People with higher eosinophil counts and more frequent past attacks tended to benefit most. In adults with EGPA, about 6 in 10 were in remission (no active vasculitis while taking 4 mg or less of prednisone a day) at both 36 and 48 weeks, a result similar to mepolizumab. In HES, 22% of people on benralizumab had a flare or left the study over 24 weeks, compared with 45% on placebo. Benralizumab is a maintenance treatment taken on an ongoing schedule, not a short course. The care team tracks attacks or flares, steroid use and symptoms to decide whether it is working well enough to continue. If asthma stays uncontrolled or worsens after starting, tell the care team, since a different approach may be needed.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Fasenra (Benralizumab), what you've noticed, or ask the community a question.